Chunting Zhu Yi Zhao Fang Yu Weijia Huang Wenjun Wu Jingsong He Zhen Cai Donghua He
10.3389/fimmu.2021.756583
Front Immunol
2022 Jan 14;12:756583.
brentuximab vedotin classic hodgkin lymphoma immune related adverse event tislelizumab tumor flare reaction
CC BY
https://pubmed.ncbi.nlm.nih.gov/35095839/
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Brentuximab Vedotin / therapeutic use Hodgkin Disease / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Brentuximab Vedotin / therapeutic use Hodgkin Disease / drug therapy Case Reports Research Support, Non-U.S. Gov't Adult Female Humans Antibodies, Monoclonal, Humanized Antineoplastic Agents, Immunological tislelizumab Brentuximab Vedotin
PMC8795608
35095839
Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report
2022